Integrated Biopharma Inc (INBP) fair value: what the stock is really worth
As of Oct 12, 2026: fair value of Integrated Biopharma Inc $0.85, price $0.18, upside +385.7%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $0.1500 – $1.16 · fair‑value band $0.7100 – $1.02 · the $0.1750 price screens below the $0.8500 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Integrated Biopharma in your weekly email
Every Wednesday you see whether Integrated Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines.
Show more
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Stock analysis
Integrated Biopharma Inc (INBP) currently trades at $0.1750, while our model-based Fair Value estimate is $0.8500, implying the stock looks roughly 79.4% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.9800 per share, and 22 of the 23 models we run sit above the $0.1750 price.
Bear case: the Earnings-Based group reads lowest at $0.4100, and 1 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.7100 (bear) to $1.02 (bull), the price of $0.1750 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Integrated Biopharma Inc reported revenue of $54.4M in FY2025 versus $63.6M in FY2021, a compound −3.8%/yr. Reported net income was $808K in FY2025, compounding −43.6%/yr from FY2021.
Key figures
Market cap $5.4M · P/S ratio 0.13 · EPS (TTM) $−0.0900 · Net margin 1.5% · Return on equity −15.0% · Return on assets (EBIT) 8.6% · Operating margin −8.9% · Revenue (TTM) $43.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 6% fair-value upside, at 386%, INBP screens cheaper than that median.
Fair Value models
Bear $0.7100Fair Value $0.8500Bull $1.02
Price $0.1750 · Upside +385.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF$0.7300$0.9900$1.3381
Growth DCF$0.7500$0.9800$1.2980
Owner Earnings$0.7400$0.9900$1.3477
All 23 models by family
DCF Models
FCF DCF$0.7300$0.9900$1.3381
Owner Earnings$0.7400$0.9900$1.3477
5Y Revenue Exit$0.6900$0.9800$1.3373
5Y EBITDA Exit$0.9100$1.36$1.8775
5Y P/E Exit$0.5700$0.7600$0.950072
10Y Revenue Exit$0.6900$0.9400$1.2567
10Y EBITDA Exit$0.8400$1.19$1.6469
10Y P/E Exit$0.6300$0.8000$0.980065
Earnings-Based
Graham-Dodd$0.1800$0.4100$0.520066
PEG = 1.0$0.0700$0.1000$0.130057
EPV$0.6500$0.7300$0.800074
Multiples
P/E Multiple$0.4100$0.5500$0.680063
P/S Multiple$0.3300$0.4400$0.550058
P/B Multiple$0.3300$0.4400$0.550055
EV/EBIT$0.9500$1.22$1.5066
EV/EBITDA$1.15$1.49$1.8467
EV/Revenue$0.7100$0.9600$1.2254
Asset-Based
NCAV (Graham)$0.3300$0.4400$0.650054
Growth DCF
Growth DCF$0.7500$0.9800$1.2980
Rev-Margin DCF$0.6900$0.9900$1.3073
Economic Profit
Residual Income$0.4800$0.4700$0.490071
ROIC Compounder$0.6500$0.7600$0.880072
Growth Earnings
Growth-Adj P/E$0.3100$0.4400$0.570067
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+8.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Start year 2020 (pandemic). Over 10 years: +3.8% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−22.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−28.4% vs −2.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 4%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−27.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −29.6% a year for the price.
Compare Integrated Biopharma Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 630 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on assets−6.7% · Bottom 25%
Net margin (TTM)−6.5% · Bottom 25%
Operating margin (TTM)−8.9% · Bottom 25%
Growth and dividend
Revenue growth−30.9% · Bottom 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Integrated Biopharma Inc (INBP) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $0.8500 versus a price of $0.1750, about +386% upside (undervalued).
What is the fair value of INBP?
Our model-based fair value for Integrated Biopharma Inc is $0.8500 (as of Oct 4, 2026), built from audited fundamentals. The current price: $0.1750.
What is the quality score of INBP?
Integrated Biopharma Inc has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Integrated Biopharma Inc (INBP)?
Our model-based price target is the fair value of $0.8500 (as of Oct 4, 2026) from 23 valuation models. Cautious scenario $0.7100, optimistic scenario $1.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Integrated Biopharma Inc stock forecast for 2026?
Our models put fair value at $0.8500, about +386% upside versus a price of $0.1750 (undervalued). Cautious scenario $0.7100, optimistic scenario $1.02. The calculation is refreshed regularly with new filings.
What is the revenue of Integrated Biopharma Inc (INBP)?
Integrated Biopharma Inc reported trailing-twelve-month revenue of about $43.9M (latest available figure, as of Oct 4, 2026).
What growth is priced into Integrated Biopharma Inc (INBP)?
For today's price to be fair in a discounted-cash-flow model, Integrated Biopharma Inc would have to grow free cash flow by -27.9 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.6 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of INBP use?
Our models discount Integrated Biopharma Inc at 8.5 %: a base by market capitalisation (nano), damped by beta 0.40, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Integrated Biopharma Inc that is -27.9 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Integrated Biopharma Inc (INBP) delivered so far?
Over the past 5 years revenue at Integrated Biopharma Inc grew +0.6 % a year. The price currently implies -27.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Integrated Biopharma Inc (INBP) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Integrated Biopharma Inc (-27.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Integrated Biopharma Inc (INBP)?
The free-cash-flow yield on the price is 34.22 %: that much free cash flow Integrated Biopharma Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Integrated Biopharma Inc (INBP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integrated Biopharma Inc it is $0.8500 per share (as of Oct 4, 2026), against a price of $0.1750. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Integrated Biopharma Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, INBP trades below its calculated fair value: price $0.1750, fair value $0.8500, a gap of about +386% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INBP?
No. The price is what the market pays today ($0.1750); the fair value is what the company's own numbers justify ($0.8500). For Integrated Biopharma Inc the two are $0.6750 per share apart. That gap is exactly why we show both numbers side by side.
How much is Integrated Biopharma Inc worth?
The market values Integrated Biopharma Inc at about $5.4M (market capitalisation, as of Oct 4, 2026). Per share that is $0.1750; our models calculate a fair value of $0.8500 per share.
What do the bullish and bearish scenarios say about INBP?
Our models span a range for Integrated Biopharma Inc: cautious scenario $0.7100, base $0.8500, optimistic $1.02 per share (as of Oct 4, 2026, price $0.1750). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Integrated Biopharma Inc (INBP)?
Balance-sheet figures for Integrated Biopharma Inc (as of Oct 4, 2026): return on equity −15.0%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is INBP from its 52-week high?
Integrated Biopharma Inc trades at $0.1750, about 54% below its 52-week high of $0.3800 and 17% above the low of $0.1500 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8500 is for.
Which stocks are comparable to Integrated Biopharma Inc?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Integrated Biopharma Inc stock attractive at the current price?
The data as of Oct 4, 2026: price $0.1750, calculated fair value $0.8500 (+386%), Quality Score 64/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INBP calculated?
We run Integrated Biopharma Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.8500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.8 % above its aggregate fair value. Integrated Biopharma Inc currently trades 79 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Integrated Biopharma Inc (INBP)?
The closing price on Oct 12, 2026 was $0.1750. Our model-based fair value is $0.8500, about +386% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Integrated Biopharma Inc right now?
The price is below even our cautious bear case ($0.7100). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Integrated Biopharma Inc
How large is the market capitalisation of Integrated Biopharma Inc (INBP)?
The market capitalisation of Integrated Biopharma Inc is $5.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Integrated Biopharma Inc (INBP)?
The price-to-sales ratio of Integrated Biopharma Inc is 0.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Integrated Biopharma Inc (INBP)?
Earnings per share at Integrated Biopharma Inc are $−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Integrated Biopharma Inc (INBP)?
The net margin of Integrated Biopharma Inc is 1.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Integrated Biopharma Inc (INBP)?
The return on equity (ROE) of Integrated Biopharma Inc is −15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Integrated Biopharma Inc (INBP)?
On an EBIT basis the return on assets of Integrated Biopharma Inc is 8.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Integrated Biopharma Inc (INBP)?
The operating margin of Integrated Biopharma Inc is −8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Integrated Biopharma Inc (INBP)?
Revenue at Integrated Biopharma Inc is growing −30.9% versus a year earlier (3y avg −1.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Integrated Biopharma Inc (INBP)?
Earnings per share at Integrated Biopharma Inc are growing −54.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Integrated Biopharma Inc (INBP) carry?
The net debt of Integrated Biopharma Inc is $3.4M (fiscal year 2021, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Integrated Biopharma Inc in the live analysis
One click puts Integrated Biopharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 4, 2026